Solid Biosciences Duchenne Trial Sees Positive Interim Update
In updated interim data from the Phase 1/2 INSPIRE DUCHENNE study, 40 participants have received SGT-003 to date. Among...
Injectable Buprenorphine Lowers OUD Healthcare Costs, Study
Patients adherent to the monthly extended-release buprenorphine injection for 12 months posted 42% lower adjusted non-MOUD medical costs compared...
Breakthrough Diabetes Study: Positive Results Past One Year
At 14 months post-transplant, a single patient in an investigator-sponsored study maintained detectable fasting and meal-stimulated C-peptide, with mixed-meal...
Vima’s Hope: First Dystonia Patient Dosed in Phase 2 Study
Phase 1 data for VIM0423 showed the oral agent was safe and well tolerated through 28 days in healthy...
Sellas Launches Pioneering AML Trial, Enrolls First Patient
SELLAS’ CDK9 inhibitor SLS009 (tambiciclib) previously delivered a 33% overall response rate across evaluable relapsed/refractory AML patients, rising to...
Aplagon Announces Dosing in Phase 2a Ischemia Trial
Aplagon has dosed the first patient in HEALING, a Phase 2a study of APAC in chronic limb-threatening ischemia secondary...
c-bio Cleared for T-Cell Therapy Trial in Cervical Cancer
Cbio has received regulatory clearance to initiate a first‑in‑human Phase I/IIa study of novoleucel in persistent or recurrent cervical...
Phase 2b Tuberculosis Trial Doses First Patient with ALPE
Prior data on alpibectir-ethionamide (AlpE) showed a 7-day early bactericidal activity signal comparable to isoniazid and a generally acceptable...
How a Single eGFR Change Is Exposing the Clinical Trial Industry’s Embedded Patient Bias Problem
A new real-world evidence study shows that removing race from the kidney function algorithm resulted in 5.3 more transplants...
New Gedatolisib Breast Cancer Data from VIKTORIA-1 Study
In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer post-CDK4/6 inhibitor, gedatolisib...